SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid staggered IPO lockup releases that make additional shares eligible for sale, with traders debating whether potential insider selling will add to the decline or is already priced in. Broader weakness in AI and semiconductor stocks and concerns about valuation and customer concentration weigh on sentiment, while some investors are buying the dip.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp futures rebound after a technology-led selloff, with traders debating whether it signals a sustained recovery or is only a short-covering bounce that could fade. Discussion also centers on Black Monday anniversary fears and upcoming Big Tech earnings, which could test sentiment around AI-related stocks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the focus, with traders watching for the 80th death event that triggers final analysis; the last disclosed count was 78, and the company has not confirmed that the threshold has been reached. The prolonged wait and company silence fuel opposing views: some see a possible survival benefit from GPS, while others worry about the delay and question speculation that ASH embargoes or the companys booth signal an upcoming readout; shares have faced sharp selling.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp rebound in index futures after a tech-led selloff has fueled discussion around the 1987 Black Monday anniversary and upcoming Big Tech earnings. Traders are split on whether the move signals a recovery or is a low-volume short-covering bounce that could fade.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad selloff in AI infrastructure and neocloud stocks, as traders debate whether high financing costs, debt exposure and uncertain returns make the sectors data-center expansion unsustainable; concerns about CoreWeaves credit risks are also weighing on peers. Bulls argue Nebius has a stronger balance sheet, durable AI demand and valuable customer relationships, while bears see further downside and a valuation reset.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel is driving attention, especially mature frontline melanoma results for the lifileucelpembrolizumab combination and preliminary sarcoma activity. Traders largely view the melanoma durability data as encouraging support for the ongoing Phase 3 trial, while debating whether the small sarcoma cohort and its lower response rate versus an earlier cut meaningfully strengthen the case for expansion.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassians push to a new 52-week high, attributed to enterprise demand and customers migrating to its cloud products, has drawn attention. Traders are split between viewing the move as a breakout and expecting resistance or a pullback after the sharp run.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas move to fresh highs is being linked to its stablecoin-powered payment service and Chinas approval for the company to prepare a domestic card-clearing business. Traders are broadly bullish on the breakout and new payment opportunities, while some caution that the rally looks extended and may pull back.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

RIOT is drawing attention amid a sharp selloff across Bitcoin miners and AI/data-center-linked stocks, with traders pointing to Bitcoin weakness, broader market pressure, and doubts about the sectors capital-intensive AI pivot. Many are frustrated that RIOT has fallen even when Bitcoin holds up, while others are buying the dip and debating whether further downside lies ahead.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume surge, with traders noting its strength even as the broader crypto market weakened and speculating that buying activity could signal something developing; no specific catalyst is confirmed. The reaction is divided between buyers anticipating a breakout and skeptics warning the move may fade like prior pumps, while some point to Flexas payment-and-collateral thesis and AMPs relationship with ANVL as longer-term context.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

YD Bio (NASDAQ:YDES) Shares Up 2.8% - Here's Why

YD Bio (NASDAQ:YDES) Shares Up 2.8% - Should You Buy...

YD Bio (NASDAQ:YDES) Shares Gap Up - What's Next?

YD Bio (NASDAQ:YDES) Shares Gap Up - Here's What Happened...

YD Bio (NASDAQ:YDES) Trading Down 3.5% - Here's What Happened

YD Bio (NASDAQ:YDES) Trading Down 3.5% - Time to Sell...

YD Bio (NASDAQ:YDES) Trading 12.5% Higher - Here's Why

YD Bio (NASDAQ:YDES) Trading 12.5% Higher - Here's Why...

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday

Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.read more...

YD Bio (NASDAQ:YDES) Sets New 52-Week Low - Here's What Happened

YD Bio (NASDAQ:YDES) Hits New 52-Week Low - Should You Sell...

YD Bio (NASDAQ:YDES) Stock Price Down 5.6% - Here's Why

YD Bio (NASDAQ:YDES) Trading Down 5.6% - Here's Why...

YD Bio (NASDAQ:YDES) Trading 7.9% Higher - Still a Buy?

YD Bio (NASDAQ:YDES) Stock Price Up 7.9% - What's Next...

YD Bio (NASDAQ:YDES) Shares Gap Up - Time to Buy?

YD Bio (NASDAQ:YDES) Shares Gap Up - Time to Buy...

YD Bio (NASDAQ:YDES) Stock Price Down 9.1% - Here's Why

YD Bio (NASDAQ:YDES) Stock Price Down 9.1% - Here's What Happened...

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YD Bio Stock Rises On Entry Into US Eye Care Segment

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$5.92
Prev Close	$6.74
Open	$6.67
Dividend Yield	0.00%
50-Day Moving Average	$4.64
Beta	0.07
Avg. Volume	682,625.03
PE Ratio	-5.99

52-Week High	$22.00
52-Week Low	$1.70
Market Capitalization	$419.39M
EPS (Annual)	-$0.1246
Price to Book	93.75
Revenue Per Employee	$39,787.80

Feed

News

Sentiment

Fundamentals

Info

YDES Fundamentals